Founded with the mission to revolutionize the treatment of peripheral arterial disease (PAD), R3 Vascular specializes in developing bioresorbable scaffold technology. Their core product, the Magnitude BRS device, features a sirolimus coating and is noted for its exceptional thinness, with a strut thickness of just 98 microns. This innovative scaffold balances strength and flexibility, aiming to improve patient outcomes in the PAD market.
R3 Vascular's proprietary polymer and manufacturing processes set them apart in the medical device industry. The company has garnered attention for its cutting-edge technology and has attracted notable investors and experts in the field. Their achievements include successful clinical trials demonstrating the efficacy and safety of their scaffolds. Overall, R3 Vascular is making significant strides in enhancing the treatment landscape for PAD, impacting patient care and advancing medical technology.
